Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Peginterferon Alfa-2a and Ribavirin in Thalassemia Patients with Hepatitis C
NCT00502788Phase 2Completed
- Sponsor
- Elevance Health
- Start
- May 2003
- Primary completion
- Jun 2006
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of peginterferon alfa-2a and ribavirin in hepatitis C (HCV), sponsored by Elevance Health. Primary endpoint: Safety of peginterferon alfa-2a and ribavirin in individuals with thalassemia (measured by changes in liver iron stores and development of iron overload-related complications) at Week 72. Started May 2003; status: completed.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00502788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00502788.